Literature DB >> 11126209

Pharmacokinetics of human leptin in mice and rhesus monkeys.

B Ahrén1, R M Baldwin, P J Havel.   

Abstract

OBJECTIVE: The pharmacokinetic characteristics of human leptin were examined in rhesus monkeys and in C57BL/6J mice fed a normal chow or a high-fat diet.
DESIGN: For the monkey study, in nine rhesus monkeys (body weight 12.4 +/- 2.4 kg; mean +/- s.d.), recombinant met-human leptin was injected intravenously or subcutaneously (1 mg/kg). For the mouse study, after 6 months of feeding C57BL/6J mice a high-fat diet (body weight 32.9 +/- 3.6 g; n = 8) or a control diet (24.5 +/- 1.2 g; n = 6), recombinant met-human leptin was administered intraperitoneally (10 microg/g). Blood samples were collected for leptin measurement at specific time points after leptin administration. MEASUREMENTS: Plasma leptin concentrations were determined by radioimmunoassay and pharmacokinetic analysis was performed.
RESULTS: Disposition of human leptin in rhesus monkeys was biphasic following intravenous administration, with a terminal phase half-life of 96.4 +/- 16.5 min and clearance of 1.8 +/- 0.2 ml/min/kg. Subcutaneously administered leptin was absorbed slowly, perhaps by a zero-order process as leptin levels appeared to plateau and remained elevated throughout the 8 h sampling period. In C57BL/6J mice, the absorption and elimination of human leptin were both first-order following intraperitoneal administration. Pharmacokinetic parameters did not differ between normal-weight mice fed a chow diet and obese mice fed a high-fat diet. The elimination half-life was 47.0 +/- 26.4 min in mice fed a high-fat diet and 49.5 +/- 12.0 min in mice fed a control diet.
CONCLUSION: The kinetics of leptin in rhesus monkeys were biphasic and clearance was similar to values previously reported in humans. The estimated half-life was 96.4 min in rhesus monkeys and 49.5 min in normal weight mice. The was no difference in leptin kinetics between high-fat fed and control mice, suggesting that the increased baseline leptin levels in the obese mice are due to increased leptin production and secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126209     DOI: 10.1038/sj.ijo.0801447

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  15 in total

Review 1.  Leptin applications in 2015: what have we learned about leptin and obesity?

Authors:  Olivia M Farr; Anna Gavrieli; Christos S Mantzoros
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-10       Impact factor: 3.243

2.  Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency : ghrelin and leptin changes in relation to obesity treatment.

Authors:  Marko Nikolic; Marko Boban; Neven Ljubicic; Vladimir Supanc; Gorana Mirosevic; Borka Pezo Nikolic; Ruzica Krpan; Ljubica Posavec; Vanja Zjacic-Rotkvic; Miroslav Bekavac-Beslin; Petar Gacina
Journal:  Obes Surg       Date:  2011-10       Impact factor: 4.129

3.  Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Wenli Wang; Benjamin R Saville; Peter J Havel
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

4.  Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.

Authors:  Sung In Lim; Young S Hahn; Inchan Kwon
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

Review 5.  Metreleptin: first global approval.

Authors:  Ken Chou; Caroline M Perry
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 6.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

7.  Leptin treatment inhibits the progression of atherosclerosis by attenuating hypercholesterolemia in type 1 diabetic Ins2(+/Akita):apoE(-/-) mice.

Authors:  John Y Jun; Zhexi Ma; Rajkumar Pyla; Lakshman Segar
Journal:  Atherosclerosis       Date:  2012-10-12       Impact factor: 5.162

Review 8.  Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Kamran Qureshi; Gary A Abrams
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

9.  Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1.

Authors:  Jingbo Yan; Fang C Mei; Hongqiang Cheng; Dieu Hung Lao; Yaohua Hu; Jingna Wei; Igor Patrikeev; Dapeng Hao; Sonja J Stutz; Kelly T Dineley; Massoud Motamedi; Jonathan D Hommel; Kathryn A Cunningham; Ju Chen; Xiaodong Cheng
Journal:  Mol Cell Biol       Date:  2012-12-21       Impact factor: 4.272

10.  Effects of energy status and diet on Bdnf expression in the ventromedial hypothalamus of male and female rats.

Authors:  Xian Liu; Zheng Zhu; Manu Kalyani; James M Janik; Haifei Shi
Journal:  Physiol Behav       Date:  2014-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.